Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

669 related articles for article (PubMed ID: 25925789)

  • 1. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
    Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
    Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapy.
    Raldow AC; Zhang D; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
    Brachytherapy; 2015; 14(6):781-7. PubMed ID: 26361718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Greatest percentage of involved core length and the risk of death from prostate cancer in men with highest Gleason score ≥ 7.
    Cheney MD; Chen MH; Zhang D; Phillips JG; Loffredo MJ; D'Amico AV
    Clin Genitourin Cancer; 2014 Aug; 12(4):234-40. PubMed ID: 24594503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen Deprivation Therapy Use in the Setting of High-dose Radiation Therapy and the Risk of Prostate Cancer-Specific Mortality Stratified by the Extent of Competing Mortality.
    Rose BS; Chen MH; Wu J; Braccioforte MH; Moran BJ; Doseretz DE; Katin MJ; Ross RH; Salenius SA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(4):778-784. PubMed ID: 27788950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease?
    Kim MM; Hoffman KE; Levy LB; Frank SJ; Pugh TJ; Choi S; Nguyen QN; McGuire SE; Lee AK; Kuban DA
    Eur J Cancer; 2012 Jul; 48(11):1664-71. PubMed ID: 22336663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer.
    Kovtun KA; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
    Cancer; 2016 Dec; 122(23):3608-3614. PubMed ID: 27490845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer.
    King MT; Chen MH; Moran BJ; Braccioforte MH; Buzurovic I; Muralidhar V; Yang DD; Mouw KW; Devlin PM; D'Amico AV; Nguyen PL; Orio PF
    Urol Oncol; 2018 Apr; 36(4):157.e15-157.e20. PubMed ID: 29276060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
    Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
    Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Comorbidity on the Risk of Mortality in Men With Unfavorable-Risk Prostate Cancer Undergoing High-Dose Radiation Therapy Alone.
    Huynh MA; Chen MH; Wu J; Braccioforte MH; Moran BJ; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1158-67. PubMed ID: 27209511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
    Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
    Falchook AD; Basak R; Mohiuddin JJ; Chen RC
    Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.
    Yang DD; Muralidhar V; Nguyen PL; Buzurovic I; Martin NE; Mouw KW; Devlin PM; Trinh QD; Orio PF; King MT
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):904-911. PubMed ID: 29063853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancer.
    Feng FY; Blas K; Olson K; Stenmark M; Sandler H; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2013 May; 86(1):64-71. PubMed ID: 23462420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors.
    Nguyen PL; Chen MH; Catalona WJ; Moul JW; Sun L; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):659-64. PubMed ID: 18692327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal therapy or external-beam radiation with brachytherapy and the risk of death from prostate cancer in men with intermediate risk prostate cancer.
    Rosenberg JE; Chen MH; Nguyen PL; Braccioforte MH; Moran BJ; D'Amico AV
    Clin Genitourin Cancer; 2012 Mar; 10(1):21-5. PubMed ID: 22130293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.
    Muralidhar V; Chen MH; Reznor G; Moran BJ; Braccioforte MH; Beard CJ; Feng FY; Hoffman KE; Choueiri TK; Martin NE; Sweeney CJ; Trinh QD; Nguyen PL
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(4):828-35. PubMed ID: 26530751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer.
    Hoffman KE; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin MJ; Ross R; D'Amico AV
    Cancer; 2010 Jun; 116(11):2590-5. PubMed ID: 20310055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of time to testosterone rebound and comorbidity on the risk of cause-specific mortality in men with unfavorable-risk prostate cancer.
    McDuff SGR; Chen MH; Renshaw AA; Loffredo MJ; Kantoff PW; D'Amico AV
    Cancer; 2018 Apr; 124(7):1391-1399. PubMed ID: 29338073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.
    Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):147-52. PubMed ID: 19744800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of the anti-androgen in men undergoing 6 months of an LHRH agonist and radiation therapy for unfavorable-risk prostate cancer and the risk of death.
    Sanford NN; Chen MH; Loffredo M; Renshaw A; Kantoff PW; D'Amico AV
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):79-84. PubMed ID: 27824043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.